Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Lowered to $39.00 at Truist Financial

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price lowered by analysts at Truist Financial from $41.00 to $39.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective points to a potential upside of 19.08% from the company’s current price.

Several other equities analysts also recently commented on AGIO. JPMorgan Chase & Co. dropped their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research report on Thursday, June 11th. Bank of America increased their price objective on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. HC Wainwright increased their target price on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Royal Bank Of Canada lifted their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $40.12.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $32.75 on Friday. The firm has a 50 day simple moving average of $34.45 and a two-hundred day simple moving average of $30.89. The company has a market cap of $1.95 billion, a P/E ratio of -4.52 and a beta of 0.54. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The business had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. On average, analysts expect that Agios Pharmaceuticals will post -6.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AGIO. T. Rowe Price Investment Management Inc. acquired a new stake in Agios Pharmaceuticals in the fourth quarter worth $25,000. Assetmark Inc. raised its holdings in shares of Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 362 shares during the period. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals during the 1st quarter worth about $40,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Agios Pharmaceuticals during the 4th quarter worth about $49,000. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $72,000.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Mitapivat revenue surged: Second-quarter worldwide net revenue for PYRUKYND and AQVESME reached $44.7 million, up from $12.5 million a year earlier and well above analyst expectations near $26.4 million. Agios also reported 442 cumulative AQVESME prescriptions in the U.S. as of June 30. Agios second-quarter results and business update
• Positive Sentiment: Important FDA catalyst approaches: The FDA granted Priority Review to mitapivat’s supplemental application in sickle cell disease, with a November 1, 2026 PDUFA target date. Approval could materially expand the drug’s addressable market. Agios projects $45 million to $50 million in 2026 revenue from pyruvate kinase deficiency. Agios revenue outlook and sickle-cell FDA decision
• Positive Sentiment: Analyst remains bullish: HC Wainwright raised its FY2030 EPS estimate to $0.66 from $0.64, maintained a Buy rating, and kept a $55 price target—above the stock’s recent trading level.
• Positive Sentiment: Strong balance sheet and pipeline: Agios held $964.8 million in cash, equivalents, and marketable securities at quarter-end, while adding cevidoplenib for immune thrombocytopenia and advancing AG-236 into Phase 2/3 testing for polycythemia vera. Agios pipeline and financial update
• Neutral Sentiment: Quarterly loss remains significant: Agios reported a second-quarter loss of $1.69 per share, although coverage differed on whether this beat or missed consensus estimates. The loss improved from $1.93 per share a year ago, but the company remains unprofitable.
• Negative Sentiment: Shareholder litigation overhang: Pomerantz LLP announced an investigation into potential claims on behalf of Agios investors, which could create reputational and legal uncertainty. Pomerantz investor investigation

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.